Publications by authors named "Christopher Fausel"

Claim this Profile
F
Fidelity of Next-Generation Sequencing to Predict Human Epidermal Growth Factor 2 Overexpression Across Solid Tumors.
Mya Tran, Christopher A Fausel, Steven Bray, Guanglong Jiang, Erica Cantor

JCO Precis Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Return of Clinically Actionable Pharmacogenetic Results From Molecular Tumor Board DNA Sequencing Data: Workflow and Estimated Costs.
Hyunwoo Koo, Tayler B Smith, John T Callaghan, Wilberforce Osei, Steven M Bray, Christopher A Fausel

Clin Pharmacol Ther· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma.
Zachary M Avigan, Suzanne Arinsburg, Darren Pan, Tomer Mark, Christopher Fausel

Bone Marrow Transplant· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination defective metastatic esophageal/gastroesophageal junction/proximal gastric adenocarcinoma.
Ahmed Bilal Khalid, Christos Fountzilas, Heather N Burney, Hirva Mamdani, Bryan P Schneider, Christopher Fausel

Front Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma.
Zachary M Avigan, Suzanne Arinsburg, Darren Pan, Tomer Mark, Christopher Fausel

Bone Marrow Transplant· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safe Handling of Hazardous Drugs: ASCO Standards.
Paul Celano, Christopher A Fausel, Erin B Kennedy, Tim M Miller, Thomas K Oliver

J Clin Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study.
Nabil Adra, Costantine Albany, Mary J Brames, Somer Case-Eads, Cynthia S Johnson, Christopher A Fausel

Support Care Cancer· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing the Budget Impact Model for Institutional Use: A Tool with Practical Applications for the Hospital Oncology Pharmacy.
Lisa M Hess, Frank N Cinfio, Stewart Wetmore, Collin Churchill, Christopher Fausel

Hosp Pharm· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of an assumption-free Bayesian approach with Optimal Sampling Schedule to a maximum a posteriori Approach for Personalizing Cyclophosphamide Dosing.
José M Laínez, Seza Orcun, Joseph F Pekny, Gintaras V Reklaitis, Attaya Suvannasankha, Christopher Fausel

Pharmacotherapy· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
Costantine Albany, Mary J Brames, Christopher Fausel, Cynthia S Johnson, Joel Picus

J Clin Oncol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Observations of second primary malignancy in patients with multiple myeloma.
Anne Ormerod, Christopher A Fausel, Rafat Abonour, Patrick J Kiel

Clin Lymphoma Myeloma Leuk· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
Lindsay L Rosenbeck, Patrick J Kiel, Iftekhar Kalsekar, Craig Vargo, John Baute, Christopher A Fausel

Biol Blood Marrow Transplant· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Iron chelation therapy in myelodysplastic syndromes.
Christopher A Fausel

Am J Health Syst Pharm· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Iron overload in myelodysplastic syndromes. Introduction.
R Donald Harvey, Christopher A Fausel

Am J Health Syst Pharm· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacology of anticancer agents in the elderly: the pharmacist's perspective.
Christopher A Fausel

Oncology (Williston Park)· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leukemia. Q&A highlights.
David Frame, Jolynn Sessions, Christopher Fausel

Am J Health Syst Pharm· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted chronic myeloid leukemia therapy: Seeking a cure.
Christopher Fausel

Am J Health Syst Pharm· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted chronic myeloid leukemia therapy: seeking a cure.
Christopher Fausel

J Manag Care Pharm· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs.
Brian G Cochran, Kevin M Sowinski, Christopher Fausel, Brian R Overholser

Am J Health Syst Pharm· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21.
Attaya Suvannasankha, Christopher Fausel, Beth E Juliar, Constantin T Yiannoutsos, William B Fisher

Oncologist· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel treatment strategies for chronic myeloid leukemia.
Christopher A Fausel

Am J Health Syst Pharm· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recurring chemotherapy-associated alopecia areata: case report and literature review.
Susannah E Motl, Christopher Fausel

Pharmacotherapy· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis